Hepatology Market Size, Competitors & Forecast to 2030

Antiviral Drugs is the fastest growing segment, North America is the largest market globally

The Global Hepatology Market, valued at USD 12.18 Billion in 2024, is projected to experience a CAGR of 8.60% to reach USD 19.98 Billion by 2030. The global hepatology market encompasses the study, prevention, diagnosis, and management of diseases affecting the liver, gallbladder, biliary tree, and pancreas, including conditions such as viral hepatitis, liver cirrhosis, fatty liver disease, and hepatocellular carcinoma. This market's expansion is primarily driven by the escalating global prevalence of liver disorders, heightened public awareness regarding liver health, and continuous advancements in diagnostic methodologies.

Key Market Drivers

The increasing prevalence of liver diseases is a primary driver expanding the global hepatology market. Conditions like Non-Alcoholic Fatty Liver Disease are rising significantly, fueled by evolving dietary patterns and sedentary lifestyles. This widespread increase in patient populations directly generates greater demand for diagnostic tools, monitoring, and therapeutic interventions. According to "Worldwide burden of non-alcoholic fatty liver disease, 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021" published on ResearchGate, in November 2024, an estimated 1.27 billion people were affected by NAFLD in 2021, highlighting this condition's immense burden on global health systems.

Key Market Challenges

The high cost associated with advanced treatments presents a notable challenge for the global hepatology market. These substantial expenses frequently lead to restricted patient access, particularly in healthcare systems with stringent reimbursement policies or where individuals incur a significant proportion of out-of-pocket costs. The considerable financial strain placed on patients, healthcare providers, and payers can delay or prevent the widespread adoption of essential, innovative therapies, irrespective of their proven clinical efficacy. According to a 2024 study published in the Journal of Managed Care & Specialty Pharmacy, the mean annual healthcare costs per person were approximately $110,403 for patients diagnosed with cirrhosis, a severe liver condition, compared to $28,340 for those without cirrhosis.

Key Market Trends

Strategic Partnerships and Mergers for Pipeline Enhancement represent a crucial trend, as pharmaceutical and biotechnology companies seek to strengthen their portfolios and accelerate the development of novel liver disease treatments. These collaborations enable firms to share risks, leverage diverse expertise, and gain access to promising drug candidates, thereby expanding their market reach and competitive advantage. According to IQVIA, biopharma merger and acquisition activity in 2023 experienced a 79% increase in aggregate deal value compared to 2022, reaching approximately $152 billion, indicating robust investment in pipeline expansion across the biopharmaceutical sector.

Key Market Players Profiled:

Astellas Pharma Inc.
Merck & Co. Inc.
Abbott Laboratories, Inc.
Bristol- Myers Squibb Company
AbbVie Inc.
Emergent BioSolutions Inc.
F. Hoffmann- La Roche AG
Eli Lilly and Company
Viatris Inc.
Gilead Sciences, Inc.

Report Scope:

In this report, the Global Hepatology Market has been segmented into the following categories:

By Treatment Type:

Antiviral Drugs
Vaccines
Immunosuppressants
Targeted Therapy
Chemotherapy
Corticosteroids
Immunoglobulins

By Disease Type:

Hepatitis
Liver Cancer
Genetic Disorders
Autoimmune Diseases
Non- Alcoholic Fatty Liver Diseases
Others

By Region:

North America
Europe
Asia Pacific
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatology Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatology Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment Type (Antiviral Drugs, Vaccines, Immunosuppressants, Targeted Therapy, Chemotherapy, Corticosteroids, Immunoglobulins)
5.2.2. By Disease Type (Hepatitis, Liver Cancer, Genetic Disorders, Autoimmune Diseases, Non- Alcoholic Fatty Liver Diseases, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map

6. North America Hepatology Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment Type
6.2.2. By Disease Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Hepatology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment Type
6.3.1.2.2. By Disease Type
6.3.2. Canada Hepatology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment Type
6.3.2.2.2. By Disease Type
6.3.3. Mexico Hepatology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment Type
6.3.3.2.2. By Disease Type

7. Europe Hepatology Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment Type
7.2.2. By Disease Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Hepatology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment Type
7.3.1.2.2. By Disease Type
7.3.2. France Hepatology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment Type
7.3.2.2.2. By Disease Type
7.3.3. United Kingdom Hepatology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment Type
7.3.3.2.2. By Disease Type
7.3.4. Italy Hepatology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment Type
7.3.4.2.2. By Disease Type
7.3.5. Spain Hepatology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment Type
7.3.5.2.2. By Disease Type

8. Asia Pacific Hepatology Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment Type
8.2.2. By Disease Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Hepatology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment Type
8.3.1.2.2. By Disease Type
8.3.2. India Hepatology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment Type
8.3.2.2.2. By Disease Type
8.3.3. Japan Hepatology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment Type
8.3.3.2.2. By Disease Type
8.3.4. South Korea Hepatology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment Type
8.3.4.2.2. By Disease Type
8.3.5. Australia Hepatology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment Type
8.3.5.2.2. By Disease Type

9. Middle East & Africa Hepatology Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment Type
9.2.2. By Disease Type
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Hepatology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment Type
9.3.1.2.2. By Disease Type
9.3.2. UAE Hepatology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment Type
9.3.2.2.2. By Disease Type
9.3.3. South Africa Hepatology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment Type
9.3.3.2.2. By Disease Type

10. South America Hepatology Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment Type
10.2.2. By Disease Type
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hepatology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment Type
10.3.1.2.2. By Disease Type
10.3.2. Colombia Hepatology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment Type
10.3.2.2.2. By Disease Type
10.3.3. Argentina Hepatology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment Type
10.3.3.2.2. By Disease Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Hepatology Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Astellas Pharma Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck & Co. Inc.
15.3. Abbott Laboratories, Inc.
15.4. Bristol- Myers Squibb Company
15.5. AbbVie Inc.
15.6. Emergent BioSolutions Inc.
15.7. F. Hoffmann- La Roche AG
15.8. Eli Lilly and Company
15.9. Viatris Inc.
15.10. Gilead Sciences, Inc.

16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

Astellas Pharma Inc.
Merck & Co. Inc.
Abbott Laboratories, Inc.
Bristol- Myers Squibb Company
AbbVie Inc.
Emergent BioSolutions Inc.
F. Hoffmann- La Roche AG
Eli Lilly and Company
Viatris Inc.
Gilead Sciences, Inc.

Table Information

Report Attribute	Details
No. of Pages	183
Published	November 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 12.18 Billion
Forecasted Market Value ( USD ) by 2030	$ 19.98 Billion
Compound Annual Growth Rate	8.6%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3969EUR$4,500USD£3,487GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4851EUR$5,500USD£4,262GBP

Hepatology Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Key Market Drivers

Key Market Challenges

Key Market Trends

Key Market Players Profiled: